MARKET

TPST

TPST

Tempest Therapeutics Inc
NASDAQ
2.260
-0.030
-1.31%
After Hours: 2.270 +0.01 +0.44% 19:50 03/13 EDT
OPEN
2.287
PREV CLOSE
2.290
HIGH
2.350
LOW
2.210
VOLUME
46.83K
TURNOVER
--
52 WEEK HIGH
12.23
52 WEEK LOW
2.120
MARKET CAP
11.14M
P/E (TTM)
-0.2173
1D
5D
1M
3M
1Y
5Y
1D
Tempest Therapeutics Selects Cincinnati Children's AGCTC As Lead Contract Development And Manufacturing Partner To Conduct Formal Technology Transfer Of TPST-2003 For Treatment Of rrMM
Benzinga · 4d ago
Tempest, Cincinnati Children’s AGCTC partner for TPST-2003 registrational study
TipRanks · 4d ago
Tempest selects Cincinnati Children’s AGCTC for TPST-2003 tech transfer ahead of planned 2026 U.S. registrational study
Reuters · 4d ago
Tempest Therapeutics selects Cincinnati Children’s AGCTC for TPST-2003 technology transfer and manufacturing support
Reuters · 4d ago
TEMPEST ANNOUNCES PARTNERSHIP FOR TPST-2003 IN PREPARATION FOR PLANNED U.S. REGISTRATIONAL STUDY IN 2026
Reuters · 4d ago
Weekly Report: what happened at TPST last week (0302-0306)?
Weekly Report · 6d ago
Weekly Report: what happened at TPST last week (0223-0227)?
Weekly Report · 03/02 10:27
Tempest Therapeutics Advances TPST-2003 CAR-T with Strong Data
TipRanks · 02/25 13:28
More
About TPST
Tempest Therapeutics, Inc. is a clinical-stage biotechnology company moving towards late-stage development with a portfolio of targeted and immune-mediated product candidates with the potential to be first-in-class to treat a range of cancers. Its programs range from early research to the lead program, amezalpat, a pivotal study in first-line hepatocellular carcinoma (HCC). Its second clinical program, TPST-1495, is a novel, small-molecule dual antagonist of the EP2 and EP4 receptors of prostaglandin E2 (PGE2), a pathway implicated in multiple cancers. Its development strategy for TPST-1495 includes evaluation in familial adenomatous polyposis (FAP), a rare genetic disorder that increases the risk of gastrointestinal cancers. Its pipeline also includes TPST-2003, TPST-2206, TPST-3003, and TPST-3206. TPST-2003 is a new dual-targeting CD19/BCMA CAR-T asset. TPST-2206 is a dual-targeting CD70/CD70 CAR-T for renal cell carcinoma. TPST-3206 is an allogeneic dual-targeting CD70/CD70.

Webull offers Tempest Therapeutics Inc stock information, including NASDAQ: TPST real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, TPST stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading TPST stock methods without spending real money on the virtual paper trading platform.